Registry of Sustained Immunity to COVID-19 Among ESKD Patients

Completed

Conditions studied: SARS-CoV-2 Infection, Anti-SARS-CoV-2 Infection

In brief

This is a multi-center, prospective registry study of subjects undergoing hemodialysis for treatment of end-stage renal disease in a DaVita center. The objective of this study is to understand whether and to what degree anti-SARS-CoV-2 antibodies mitigate the risk of subsequent SARS-CoV-2 infection and COVID disease within the ESKD population.

Key facts

Study ID

NCT04495764

Run by

Davita Clinical Research

People needed

2315

Starts

2020-07-20

Expected to finish

2021-02-12

Last updated by the study team

2021-05-27

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Between ≥18 and 80 years of age, inclusive.
• Ability to provide informed consent.
• Currently receiving hemodialysis treatment for end-stage kidney disease at a DaVita dialysis center.

Where it is running

• DCR Victorville — Victorville, California, United States
• DCR Connecticut — Bridgeport, Connecticut, United States
• DCR Twin Cities — Minneapolis, Minnesota, United States
• DCR Las Vegas — Las Vegas, Nevada, United States
• DCR Bronx — The Bronx, New York, United States
• DCR Canton — Canton, Ohio, United States
• DCR El Paso — El Paso, Texas, United States
• DCR Lewisville — Lewisville, Texas, United States
• DCR San Antonio — San Antonio, Texas, United States
• DCR San Antonio — San Antonio, Texas, United States
• DCR Norfolk — Norfolk, Virginia, United States
• DCR Milwaukee — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.